Literature DB >> 16952283

Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients.

Joel J Heidelbaugh1, John M Inadomi.   

Abstract

BACKGROUND: Although administration of stress ulcer prophylaxis (SUP) has been recommended for specific patients in the intensive care unit (ICU) setting, this practice has been extrapolated to care of non-ICU patients without evidence to support need or efficacy. AIMS: To examine the practice of SUP in non-ICU patients in a university hospital setting, with specific attention to resource utilization.
METHODS: Retrospective chart review of adult non-ICU admissions to one family medicine and five general internal medicine teaching services over a consecutive 4-month period. Proportion of patients prescribed SUP was ascertained after exclusion of patients admitted on antisecretory therapy (AST) or prescribed AST for non-SUP indications. Annual cost estimates were calculated assuming full compliance.
RESULTS: Of 1,769 patient admissions, 22% received SUP and 54% of these were discharged home on AST. None of these patients met evidence-based criteria for appropriate SUP. Inpatient SUP cost Dollars 11,024 over the 4 months of the study (Dollars 44,096 annually), and outpatient costs based on discharge prescriptions were Dollars 16,924 (Dollars 67,695 annually), yielding a total cost expenditure of Dollars 27,948 (Dollars 111,791 annually).
CONCLUSION: SUP is overutilized in the non-ICU setting, and patients are often discharged unnecessarily on AST, resulting in significant cost expenditure. Interventions to ensure appropriate use of SUP should decrease resource expenditures without detrimental impact on quality of care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952283     DOI: 10.1111/j.1572-0241.2006.00839.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  47 in total

1.  Issues Related to BID Dosing of PPIs.

Authors:  John Inadomi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-06

2.  Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.

Authors:  Patrick S Yachimski; Elizabeth A Farrell; Daniel P Hunt; Andrea E Reid
Journal:  Arch Intern Med       Date:  2010-05-10

3.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

4.  The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.

Authors:  Maria Meli; Maria Pia Raffa; Renato Malta; Ilaria Morreale; Luigi Aprea; Natale D'Alessandro
Journal:  Int J Clin Pharm       Date:  2015-08-30

5.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

6.  Stress ulcer prophylaxis in the intensive care unit.

Authors:  Ladan Mohebbi; Kristen Hesch
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-10

7.  Interventions to curb the overuse of Acid-suppressive medications on an inpatient general medicine service.

Authors:  Randolph E Regal; Amanda D Osta; Vikas I Parekh
Journal:  P T       Date:  2010-02

8.  Impact of multi-approach strategy on acid suppressive medication use in a teaching hospital in Qatar.

Authors:  Imran F Khudair; Nagham D Sadik; Yolande Hanssens; Saif A Muhsin; Issa Matar
Journal:  Int J Clin Pharm       Date:  2011-07-02

9.  Use of acid suppressive therapy in hospitalized non-critically ill patients.

Authors:  Marwan Sheikh-Taha; Sarah Alaeddine; Julie Nassif
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-12-06

10.  Physicians' opinions of stress ulcer prophylaxis: survey results from a large urban medical center.

Authors:  Charles P Koczka; Laura B Geraldino-Pardilla; Adam J Goodman
Journal:  Dig Dis Sci       Date:  2012-10-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.